Pfizer and BioNTech Receive European Commission Approval for 2026–2027 XFG-Adapted COVID-19 Vaccine Across Europe
Pfizer Inc. and BioNTech SE have announced that the European Commission (EC) has granted marketing authorization for their updated 2026–2027 COVID-19 vaccine, specifically designed to target the XFG variant of SARS-CoV-2. The authorization marks another important milestone in the ongoing effort to keep COVID-19 vaccination strategies aligned with the virus’s evolving variants and to provide continued protection for populations across Europe.
The newly authorized vaccine is approved for active immunization against COVID-19 in individuals aged six months and older. It follows recommendations issued by the European Medicines Agency’s (EMA) Emergency Task Force (ETF), which advised vaccine manufacturers to update their seasonal COVID-19 vaccines to target the XFG variant, a descendant of the JN.1 lineage. According to the ETF, available scientific evidence indicates that an XFG-targeted vaccine is expected to provide the broadest and most effective protection against circulating SARS-CoV-2 strains during the 2026–2027 respiratory virus season.
Authorization Covers the Entire European Economic Area
The European Commission’s decision applies across all 27 European Union member states and extends to Iceland, Liechtenstein, and Norway. This broad authorization enables health authorities throughout Europe to incorporate the updated vaccine into their national immunization strategies ahead of the expected increase in COVID-19 transmission during the autumn and winter months.
Pfizer and BioNTech have already begun manufacturing the updated monovalent XFG-adapted vaccine in anticipation of regulatory approval. By initiating production ahead of authorization, the companies aim to ensure adequate vaccine availability when seasonal demand rises.
Countries participating under the existing European Commission procurement agreement will receive vaccine supplies through the centralized purchasing framework, while others may procure doses according to their individual national vaccination policies.
Updated Vaccine Reflects Latest Scientific Recommendations
COVID-19 continues to evolve through the emergence of new variants and subvariants. Regulatory agencies worldwide regularly assess circulating strains to determine whether vaccine compositions should be modified to maintain optimal protection.
For the 2026–2027 vaccination season, the EMA’s Emergency Task Force concluded that vaccines targeting the XFG variant would likely provide the strongest immune protection against the viruses currently spreading in Europe and other regions.
The recommendation reflects continuous surveillance of SARS-CoV-2 evolution and aims to ensure that updated vaccines remain closely matched to dominant circulating variants.
By updating the vaccine composition annually, health authorities seek to reduce the burden of COVID-19, particularly among individuals at higher risk for severe illness.
Approval Supported by Extensive Scientific Evidence
The European Commission’s authorization follows a positive recommendation issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP) on July 23, 2026.
The recommendation was based on a comprehensive package of evidence submitted jointly by Pfizer and BioNTech. The data included:
- Clinical trial findings supporting vaccine safety and immune response.
- Non-clinical laboratory research.
- Manufacturing and quality control information.
- Real-world evidence collected from previous COVID-19 vaccine use.
- Immunogenicity studies evaluating the updated XFG-adapted formulation.
Laboratory studies demonstrated that the monovalent XFG vaccine generated strong neutralizing immune responses against multiple currently circulating SARS-CoV-2 lineages.
These included:
- XFG
- XFG.1.1
- NB.1.8.1
- PQ.17
- PQ.2.8.1
- Additional contemporary variants currently circulating worldwide.
These findings support the expectation that the updated vaccine will offer broad protection despite the continued evolution of the virus.
Continued Commitment to Global COVID-19 Preparedness
In addition to securing approval within Europe, Pfizer and BioNTech have submitted regulatory applications for the updated vaccine to health authorities in multiple countries around the world.
The companies continue to closely monitor global epidemiological trends, emerging variants, and public health recommendations to ensure vaccine supply aligns with evolving healthcare needs.
Since the beginning of the COVID-19 pandemic, both organizations have maintained an ongoing strategy of adapting their mRNA vaccine platform as new variants emerge, enabling rapid updates based on scientific evidence and regulatory guidance.
Manufacturing Begins Ahead of Respiratory Virus Season
Recognizing the importance of timely vaccine availability, Pfizer and BioNTech initiated manufacturing of the XFG-adapted vaccine before receiving final authorization.
This proactive approach is intended to avoid supply delays and ensure healthcare providers can begin administering the updated vaccine as seasonal respiratory virus activity increases.
Respiratory infections, including COVID-19, influenza, and respiratory syncytial virus (RSV), typically surge during colder months, making early vaccine availability an important component of seasonal public health preparedness.
Built on Proven mRNA Technology
The updated vaccine continues to utilize BioNTech’s proprietary messenger RNA (mRNA) technology, which has formed the basis of the companies’ COVID-19 vaccine program since its initial development.
The mRNA platform enables relatively rapid modification of vaccine composition as new variants emerge, allowing manufacturers to respond efficiently to changes in viral evolution.
Under the longstanding collaboration between Pfizer and BioNTech:
- BioNTech serves as the Marketing Authorization Holder in the European Union, the United States, the United Kingdom, and several additional markets.
- Pfizer supports global manufacturing, distribution, commercialization, and regulatory activities across numerous countries.
Their partnership has resulted in one of the world’s most widely distributed COVID-19 vaccines, with billions of doses supplied globally since the pandemic began.
Current U.S. Indications
In the United States, COMIRNATY® remains approved for vaccination against COVID-19 in specific populations identified as being at higher risk for severe disease.
Current indications include:
- Adults aged 65 years and older.
- Individuals between 5 and 64 years of age who have at least one underlying medical condition associated with an increased risk of severe COVID-19 outcomes.
Healthcare providers continue to follow recommendations from public health authorities regarding eligibility, booster schedules, and seasonal vaccination.
Important Safety Information
As with all vaccines, healthcare professionals carefully assess each individual before administration.
COMIRNATY should not be administered to individuals who have experienced a severe allergic reaction following a previous dose of the vaccine or to any component contained in the formulation.
Although uncommon, severe allergic reactions may occur shortly after vaccination. For this reason, vaccine recipients are typically monitored for a brief observation period after receiving the injection.
Rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) have also been reported following administration of mRNA COVID-19 vaccines, particularly among males between 12 and 24 years of age. Most reported cases have occurred within the first week following vaccination and have generally resolved with appropriate medical care.
Individuals should seek prompt medical attention if symptoms such as chest pain, shortness of breath, or an unusually rapid or irregular heartbeat develop after vaccination.
Healthcare providers also advise patients to discuss any underlying medical conditions, allergies, pregnancy, breastfeeding, immune disorders, bleeding conditions, or previous vaccine reactions before receiving the vaccine.
Commonly reported side effects remain generally mild to moderate and may include injection-site pain, fatigue, headache, muscle aches, chills, fever, nausea, joint pain, swollen lymph nodes, decreased appetite, dizziness, vomiting, diarrhea, or redness and swelling at the injection site. As with other injectable vaccines, fainting may occasionally occur immediately after vaccination.
Supporting Seasonal COVID-19 Prevention
The European Commission’s approval of the XFG-adapted COVID-19 vaccine represents another important step in maintaining updated protection against evolving SARS-CoV-2 variants. By aligning vaccine composition with the latest scientific recommendations from the EMA’s Emergency Task Force, Pfizer and BioNTech aim to help European healthcare systems prepare for the upcoming respiratory disease season.
With manufacturing already underway and regulatory submissions progressing in additional markets, the companies continue their efforts to ensure broad access to updated COVID-19 vaccination options. The authorization also reinforces the flexibility of mRNA vaccine technology, allowing rapid adaptation to emerging viral variants while supporting ongoing public health initiatives aimed at reducing severe illness, hospitalizations, and COVID-19-related complications across diverse age groups.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.